Goldman Sachs initiated coverage of Arcutis Biotherapeutics (ARQT) with a Neutral rating and $18 price target The company’s lead asset Zoryve has a favorable profile and is preferred by many dermatologists over generic topicals and steroids, but its growth going forward may be challenged, the analyst tells investors in a research note. The firm awaits clarity on Zoryve before recommending Arcutis shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study
- Arcutis Biotherapeutics assumed with an Overweight at Morgan Stanley
- Arcutis announces ZORYVE cream receives strong recommendation from AAD
- Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting
- Arcutis Biotherapeutics enrolls first child in INTEGUMENT-INFANT